Skip to main content
Top
Published in: Dermatology and Therapy 12/2022

Open Access 04-11-2022 | Atopic Dermatitis | Original Research

Determining Severity Strata for Three Atopic Dermatitis Patient-Reported Outcome Questionnaires: Defining Severity Score Ranges for the Worst Pruritus Numerical Rating Scale and the Atopic Dermatitis Symptom and Impact Scales (ADerm-SS and ADerm-IS)

Authors: Jonathan I. Silverberg, Eric L. Simpson, Brian M. Calimlim, Leighann Litcher-Kelly, Xiaoran Li, Xiaowu Sun, Yael A. Leshem

Published in: Dermatology and Therapy | Issue 12/2022

Login to get access

Abstract

Introduction

Three patient-reported outcome (PRO) questionnaires—Worst Pruritus Numerical Rating Scale (WP-NRS), Atopic Dermatitis Symptom Scale (ADerm-SS), and Atopic Dermatitis Impact Scale (ADerm-IS)—were developed to assess the symptoms and impacts of atopic dermatitis (AD). Severity strata for these PROs are needed to aid in their interpretation.

Methods

Using data from a global, randomized, double-blind, placebo-controlled, phase 3 clinical trial (NCT03568318) of patients with moderate–severe AD (age ≥ 12 years), equipercentile linking analyses were conducted to define severity strata applying the Patient Global Impression of Severity as an anchor. Analyses were conducted separately for adults and adolescents, and then harmonized between the two age groups.

Results

The sample included 769 adults and 113 adolescents. For the WP-NRS, 0 was associated with absent, 1–2 with minimal, 3 with mild, 4–7 with moderate, and 8–10 with severe. For the ADerm-SS Skin Pain, 0 was associated with absent, 1 with minimal, 2 with mild, 3–6 with moderate, and 7–10 with severe. For ADerm-SS 7-Item Total Symptom Score (TSS-7), 0–1 was associated with absent, 2–11 with minimal, 12–22 with mild, 23–47 with moderate, and 48–70 with severe. For ADerm-IS Sleep, 0 was associated with absent, 1–3 with minimal, 4–6 with mild, 7–20 with moderate, and 21–30 with severe. For ADerm-IS Daily Activities, 0 was associated with absent, 1–2 with minimal, 3–7 with mild, 8–25 with moderate, and 26–40 with severe. For ADerm-IS Emotional State, 0 was associated with absent, 1–2 with minimal, 3–8 with mild, 9–22 with moderate, and 23–30 with severe.

Conclusions

These severity strata provide score interpretations of the WP-NRS, ADerm-SS, and ADerm-IS, translating these scores to simple and intuitive outcomes, which can inform clinical studies and clinical practice.

Trial Registration Number

NCT03568318.
Appendix
Available only for authorised users
Literature
1.
go back to reference Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(Suppl 1):8–16.CrossRefPubMed Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(Suppl 1):8–16.CrossRefPubMed
3.
go back to reference Chopra R, Vakharia PP, Sacotte R, Patel N, Immaneni S, White T, et al. Relationship between EASI and SCORAD severity assessments for atopic dermatitis. J Allergy Clin Immunol. 2017;140(6):1708-10.e1.CrossRefPubMedPubMedCentral Chopra R, Vakharia PP, Sacotte R, Patel N, Immaneni S, White T, et al. Relationship between EASI and SCORAD severity assessments for atopic dermatitis. J Allergy Clin Immunol. 2017;140(6):1708-10.e1.CrossRefPubMedPubMedCentral
4.
go back to reference Vakharia PP, Chopra R, Sacotte R, Patel KR, Singam V, Patel N, et al. Burden of skin pain in atopic dermatitis. Ann Allergy Asthma Immunol. 2017;119(6):548-52.e3.CrossRefPubMedPubMedCentral Vakharia PP, Chopra R, Sacotte R, Patel KR, Singam V, Patel N, et al. Burden of skin pain in atopic dermatitis. Ann Allergy Asthma Immunol. 2017;119(6):548-52.e3.CrossRefPubMedPubMedCentral
5.
go back to reference Foley C, Tundia N, Simpson E, Teixeira HD, Litcher-Kelly L, Bodhani A. Development and content validity of new patient-reported outcome questionnaires to assess the signs and symptoms and impact of atopic dermatitis: the Atopic Dermatitis Symptom Scale (ADerm-SS) and the Atopic Dermatitis Impact Scale (ADerm-IS). Curr Med Res Opin. 2019;35(7):1139–48.CrossRefPubMed Foley C, Tundia N, Simpson E, Teixeira HD, Litcher-Kelly L, Bodhani A. Development and content validity of new patient-reported outcome questionnaires to assess the signs and symptoms and impact of atopic dermatitis: the Atopic Dermatitis Symptom Scale (ADerm-SS) and the Atopic Dermatitis Impact Scale (ADerm-IS). Curr Med Res Opin. 2019;35(7):1139–48.CrossRefPubMed
6.
go back to reference Gerbens LA, Prinsen CA, Chalmers JR, Drucker AM, von Kobyletzki LB, Limpens J, et al. Evaluation of the measurement properties of symptom measurement instruments for atopic eczema: a systematic review. Allergy. 2017;72(1):146–63.CrossRefPubMed Gerbens LA, Prinsen CA, Chalmers JR, Drucker AM, von Kobyletzki LB, Limpens J, et al. Evaluation of the measurement properties of symptom measurement instruments for atopic eczema: a systematic review. Allergy. 2017;72(1):146–63.CrossRefPubMed
7.
go back to reference Heinl D, Prinsen CA, Deckert S, Chalmers JR, Drucker AM, Ofenloch R, et al. Measurement properties of adult quality-of-life measurement instruments for eczema: a systematic review. Allergy. 2016;71(3):358–70.CrossRefPubMed Heinl D, Prinsen CA, Deckert S, Chalmers JR, Drucker AM, Ofenloch R, et al. Measurement properties of adult quality-of-life measurement instruments for eczema: a systematic review. Allergy. 2016;71(3):358–70.CrossRefPubMed
8.
go back to reference Silverberg JI, DeLozier A, Sun L, Thyssen JP, Kim B, Yosipovitch G, et al. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis. Health Qual Life Outcomes. 2021;19(1):247.CrossRefPubMedPubMedCentral Silverberg JI, DeLozier A, Sun L, Thyssen JP, Kim B, Yosipovitch G, et al. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis. Health Qual Life Outcomes. 2021;19(1):247.CrossRefPubMedPubMedCentral
9.
go back to reference Taieb A, Boralevi F, Seneschal J, Merhand S, Georgescu V, Taieb C, et al. Atopic dermatitis burden scale for adults: development and validation of a new assessment tool. Acta Derm Venereol. 2015;95(6):700–5.CrossRefPubMed Taieb A, Boralevi F, Seneschal J, Merhand S, Georgescu V, Taieb C, et al. Atopic dermatitis burden scale for adults: development and validation of a new assessment tool. Acta Derm Venereol. 2015;95(6):700–5.CrossRefPubMed
10.
go back to reference Yosipovitch G, Reaney M, Mastey V, Eckert L, Abbe A, Nelson L, et al. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761–9.CrossRefPubMed Yosipovitch G, Reaney M, Mastey V, Eckert L, Abbe A, Nelson L, et al. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761–9.CrossRefPubMed
11.
go back to reference Chalmers JR, Simpson E, Apfelbacher CJ, Thomas KS, von Kobyletzki L, Schmitt J, et al. Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). Br J Dermatol. 2016;175(1):69–79.CrossRefPubMed Chalmers JR, Simpson E, Apfelbacher CJ, Thomas KS, von Kobyletzki L, Schmitt J, et al. Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). Br J Dermatol. 2016;175(1):69–79.CrossRefPubMed
12.
go back to reference Spuls PI, Gerbens LAA, Simpson E, Apfelbacher CJ, Chalmers JR, Thomas KS, et al. Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement. Br J Dermatol. 2017;176(4):979–84.CrossRefPubMed Spuls PI, Gerbens LAA, Simpson E, Apfelbacher CJ, Chalmers JR, Thomas KS, et al. Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement. Br J Dermatol. 2017;176(4):979–84.CrossRefPubMed
13.
go back to reference US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. Silver Spring: Office of Communications, Division of Drug Information; 2009. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Center for Devices and Radiological Health. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. Silver Spring: Office of Communications, Division of Drug Information; 2009.
14.
go back to reference Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: Part 1-Eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967–77.CrossRefPubMed Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: Part 1-Eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967–77.CrossRefPubMed
15.
go back to reference Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force Report: Part 2-Assessing respondent understanding. Value Health. 2011;14(8):978–88.CrossRefPubMed Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force Report: Part 2-Assessing respondent understanding. Value Health. 2011;14(8):978–88.CrossRefPubMed
16.
go back to reference Silverberg JI, Simpson EL, McLafferty M, Medrano P, Su S, Calimlim BM, et al. Content validity of the Atopic Dermatitis Symptom Scale (ADerm-SS) and Atopic Dermatitis Impact Scale (ADerm-IS) in adolescents to assess the symptoms and impacts of atopic dermatitis. In: Revolutionizing Atopic Dermatitis (RAD) Congress; 13–14 Dec 2020; Virtual. Silverberg JI, Simpson EL, McLafferty M, Medrano P, Su S, Calimlim BM, et al. Content validity of the Atopic Dermatitis Symptom Scale (ADerm-SS) and Atopic Dermatitis Impact Scale (ADerm-IS) in adolescents to assess the symptoms and impacts of atopic dermatitis. In: Revolutionizing Atopic Dermatitis (RAD) Congress; 13–14 Dec 2020; Virtual.
17.
go back to reference Silverberg JI, Simpson EL, Litcher-Kelly L, McDonald J, Calimlim BM, Leshem YA. Psychometric evaluation of three patient-reported outcome questionnaires assessing the symptoms and impacts of atopic dermatitis in adults and adolescents. In: Revolutionizing Atopic Dermatitis (RAD) Congress; 13–14 Dec 2020; Virtual. Silverberg JI, Simpson EL, Litcher-Kelly L, McDonald J, Calimlim BM, Leshem YA. Psychometric evaluation of three patient-reported outcome questionnaires assessing the symptoms and impacts of atopic dermatitis in adults and adolescents. In: Revolutionizing Atopic Dermatitis (RAD) Congress; 13–14 Dec 2020; Virtual.
18.
go back to reference Chopra R, Vakharia PP, Sacotte R, Patel N, Immaneni S, White T, et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol. 2017;177(5):1316–21.CrossRefPubMed Chopra R, Vakharia PP, Sacotte R, Patel N, Immaneni S, White T, et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol. 2017;177(5):1316–21.CrossRefPubMed
19.
go back to reference Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172(5):1353–7.CrossRefPubMed Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172(5):1353–7.CrossRefPubMed
20.
go back to reference Silverberg JI, Gelfand JM, Margolis DJ, Fonacier L, Boguniewicz M, Schwartz LB, et al. Severity strata for POEM, PO-SCORAD, and DLQI in US adults with atopic dermatitis. Ann Allergy Asthma Immunol. 2018;121(4):464-8.e3.CrossRefPubMed Silverberg JI, Gelfand JM, Margolis DJ, Fonacier L, Boguniewicz M, Schwartz LB, et al. Severity strata for POEM, PO-SCORAD, and DLQI in US adults with atopic dermatitis. Ann Allergy Asthma Immunol. 2018;121(4):464-8.e3.CrossRefPubMed
21.
go back to reference Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10290):2169–81.CrossRefPubMed Reich K, Teixeira HD, de Bruin-Weller M, Bieber T, Soong W, Kabashima K, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10290):2169–81.CrossRefPubMed
23.
go back to reference Kolen MJ, Brennan RL. Testing equating, scaling, and linking: methods and practices. New York: Springer-Verlag; 2014.CrossRef Kolen MJ, Brennan RL. Testing equating, scaling, and linking: methods and practices. New York: Springer-Verlag; 2014.CrossRef
24.
go back to reference Linn RL. Linking results of distinct assessments. Appl Meas Educ. 1993;6(1):83–102.CrossRef Linn RL. Linking results of distinct assessments. Appl Meas Educ. 1993;6(1):83–102.CrossRef
25.
go back to reference Leucht S, Kane JM, Etschel E, Kissling W, Hamann J, Engel RR. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacol. 2006;31(10):2318–25.CrossRef Leucht S, Kane JM, Etschel E, Kissling W, Hamann J, Engel RR. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacol. 2006;31(10):2318–25.CrossRef
26.
go back to reference McGee S. Evidence-based physical diagnosis e-book. Elsevier Health Sciences; 2021. McGee S. Evidence-based physical diagnosis e-book. Elsevier Health Sciences; 2021.
27.
go back to reference Grant L, Seiding Larsen L, Trennery C, Silverberg JI, Abramovits W, Simpson EL, et al. Conceptual model to illustrate the symptom experience and humanistic burden associated with atopic dermatitis in adults and adolescents. Dermatitis. 2019;30(4):247–54.CrossRefPubMedPubMedCentral Grant L, Seiding Larsen L, Trennery C, Silverberg JI, Abramovits W, Simpson EL, et al. Conceptual model to illustrate the symptom experience and humanistic burden associated with atopic dermatitis in adults and adolescents. Dermatitis. 2019;30(4):247–54.CrossRefPubMedPubMedCentral
29.
go back to reference Charman CR, Venn AJ, Ravenscroft JC, Williams HC. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol. 2013;169(6):1326–32.CrossRefPubMedPubMedCentral Charman CR, Venn AJ, Ravenscroft JC, Williams HC. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol. 2013;169(6):1326–32.CrossRefPubMedPubMedCentral
30.
go back to reference Silverberg JI. Validity and reliability of a novel numeric rating scale to measure skin-pain in adults with atopic dermatitis. Arch Dermatol Res. 2021;313(10):855–61.CrossRefPubMed Silverberg JI. Validity and reliability of a novel numeric rating scale to measure skin-pain in adults with atopic dermatitis. Arch Dermatol Res. 2021;313(10):855–61.CrossRefPubMed
31.
go back to reference Vakharia PP, Chopra R, Sacotte R, Patel N, Immaneni S, White T, et al. Severity strata for five patient-reported outcomes in adults with atopic dermatitis. Br J Dermatol. 2018;178(4):925–30.CrossRefPubMedPubMedCentral Vakharia PP, Chopra R, Sacotte R, Patel N, Immaneni S, White T, et al. Severity strata for five patient-reported outcomes in adults with atopic dermatitis. Br J Dermatol. 2018;178(4):925–30.CrossRefPubMedPubMedCentral
32.
go back to reference Bjorner JB. Solving the Tower of Babel problem for patient-reported outcome measures: comments on: linking scores with patient-reported health outcome instruments: a validation study and comparison of three linking methods. Psychometrika. 2021;86(3):747–53.CrossRefPubMed Bjorner JB. Solving the Tower of Babel problem for patient-reported outcome measures: comments on: linking scores with patient-reported health outcome instruments: a validation study and comparison of three linking methods. Psychometrika. 2021;86(3):747–53.CrossRefPubMed
33.
go back to reference Schalet BD, Lim S, Cella D, Choi SW. Linking scores with patient-reported health outcome instruments: a validation study and comparison of three linking methods. Psychometrika. 2021;86(3):717–46.CrossRefPubMed Schalet BD, Lim S, Cella D, Choi SW. Linking scores with patient-reported health outcome instruments: a validation study and comparison of three linking methods. Psychometrika. 2021;86(3):717–46.CrossRefPubMed
34.
go back to reference Price L, Lurie A, Wilkins C. EQUIPERCENT: a SAS program for calculating equivalent scores using the equipercentile method. Appl Psychol Meas. 2001;25:332.CrossRef Price L, Lurie A, Wilkins C. EQUIPERCENT: a SAS program for calculating equivalent scores using the equipercentile method. Appl Psychol Meas. 2001;25:332.CrossRef
Metadata
Title
Determining Severity Strata for Three Atopic Dermatitis Patient-Reported Outcome Questionnaires: Defining Severity Score Ranges for the Worst Pruritus Numerical Rating Scale and the Atopic Dermatitis Symptom and Impact Scales (ADerm-SS and ADerm-IS)
Authors
Jonathan I. Silverberg
Eric L. Simpson
Brian M. Calimlim
Leighann Litcher-Kelly
Xiaoran Li
Xiaowu Sun
Yael A. Leshem
Publication date
04-11-2022
Publisher
Springer Healthcare
Published in
Dermatology and Therapy / Issue 12/2022
Print ISSN: 2193-8210
Electronic ISSN: 2190-9172
DOI
https://doi.org/10.1007/s13555-022-00836-5

Other articles of this Issue 12/2022

Dermatology and Therapy 12/2022 Go to the issue